LearnGlossaryMarketStocksSuperinvestorsSign in

RARE

Ultragenyx Pharmaceutical Inc.

Healthcare · $1.4B market cap

Verdict

We can't put a fair value on RARE right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-15.3% a year✗
Sales growth22.8% a year✓
Free cash flow growth—?
Return on invested capital-45.3%✗

Follow RARE

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 3, 2026: no open-market purchases and 1 sale worth $2K. Why purchases matter

Sales

Huizenga Theodore Alan

SVP, Chief Accounting Officer · 2026-09-03

Sold

$2K

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works